A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib

Advanced non-small cell lung cancer (NSCLC) is a devastating disease that is incurable and associated with poor outcomes worldwide [1]. Targeted therapies with predictive biomarkers have changed the health care strategy for metastatic NSCLC patients [2]. An anaplastic lymphoma kinase (ALK) gene rearrangement is a distinct driving mutation that occurs in as many as 8% of patients with NSCLC. Of note, different fusion partners can influence the response to ALK inhibition in patients with NSCLC [3].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

AbstractAnaplastic lymphoma kinase (ALK) rearrangements have been reported in 5% to 6% of non ‐small cell lung cancer (NSCLC) patients. However, the concurrent existence of twoALK fusions within the same patient have rarely previously been reported. Moreover, considering the diversities ofALK mutations, it is necessary to evaluate the response of both double and new types ofALK fusions to ALK ‐tyrosine kinase inhibitors (ALK‐TKIs). Here, we report a case of a 64‐year‐old Chinese woman who was diagnosed with lung adenocarcinoma (ADC) who concurrently harbored two types ofALK‐rearrangements, including an unreport...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
Rearrangements in ROS1 oncogene, reported in 1 –2% of patients with non-small cell lung cancer (NSCLC), define a separate molecular sub-group of NSCLC [1]. Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor with the ability to cross the blood-brain barrier and have sub-nanomolar enzymatic efficacy in ta rgeting rearrangements in ALK and ROS1 [2]. ROS1 G2032R has been reported as the most commonly acquired mutation that mediates resistance to crizotinib therapy [3–5]; however, mechanisms that mediate lorlatinib resistance among patients with ROS1 rearrangement are rarely reported.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsThis study indicated that CT ‐707 is clinically effective as a new antitumor drug for Chinese lung adenocarcinoma patients with ALK rearrangement. It is safe and reliable and the dose‐expansion phase recruitment has started.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Approximately 2% to 8% of patients with metastatic nonsquamous non –small-cell lung cancer (NSCLC) harbor a rearrangement in the anaplastic lymphoma kinase (ALK) gene in their tumors that may render them susceptible to targeted treatment with tyrosine kinase inhibitors [1–5]. Patients with ALK-rearrangements have been described as being younger, having a histor y of never or light smoking, and being likely to have adenocarcinoma with signet ring or acinar histology, based on previous studies [3,4,6].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
AbstractAnti ‐programmed cell death 1 (PD‐1) and its ligand (PD‐L1) has emerged as a novel immunotherapy for non‐small cell lung cancer (NSCLC). However, the proportion of patients who may benefit from immunotherapy is limited and the factors sensitive or resistant to immunotherapy are not completely cle ar. Therefore, to identify reliable biomarkers as predictors of clinical response and resistance to anti‐PD‐1/PD‐L1 therapies have become increasingly important. Here, we report a case of a patient with bone metastatic NSCLC, who achieved a pathologic complete response after preoperative pembr olizumab treatm...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
Conclusion: The miR-1323 promoted LUAD migration through inhibiting Cbl-b expression. High miR-1323 expression predicted poor prognosis in LUAD patients.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: Long non-coding RNA DLEU1 is likely to represent an available biomarker or a potential therapeutic target in multiple tumors. PMID: 31969095 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
The development of targeted therapies has revolutionized the treatment of patients with lung cancer, especially non-small-cell lung cancer (NSCLC). Anaplastic lymphoma kinase (ALK) is a research hotspot of molecular targeted therapy for lung cancer. ALK tyrosine kinase inhibitors (TKIs) are highly effective for ALK-rearranged NSCLC-positive patients. These targeted therapies have significant clinical effects; however, they inevitably lead to acquired resistance. In previous studies, the histological transformation after ALK inhibitor treatment was mostly based on small-cell lung cancer (SCLC).
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
This study was undertaken to determine ICI efficacy against epidermal growth-factor receptor (EGFR)/anaplastic lymphoma kinase (ALK)/c-ros oncogene 1 (ROS1)-mutated NSCLC patients in the real-world setting. In this retrospective, multicenter study on adults with ICI-treated EGFR-mutated or ALK- or ROS1-translated NSCLCs, we analyzed clinical characteristics and outcomes: ICI-treatment duration, and progression-free survival (PFS), objective response rate, duration of response, and overall survival (OS) from immunotherapy initiation. Fifty-one NSCLC patients (mean age, 58.0 years) were included from 20 French centers: 61%...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Conclusion: Concurrent treatment with WBRT and ALK-TKI may be associated with acute severe ear toxicity in patients with BMs of ALKr-NSCLC.
Source: In Vivo - Category: Research Authors: Tags: Clinical Studies Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Genetics | Health Management | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer